What is the 13F Pro Quality Score for OGEN?

13F Pro ranks ORAGENICS INC (OGEN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OGEN's current score at https://13fpro.ai/research/OGEN (free sign-up required for the full ranking).

Where does 13F Pro source OGEN data?

All ORAGENICS INC fundamentals and ownership data come directly from SEC EDGAR. ORAGENICS INC files with the SEC under CIK 1174940. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OGEN in?

ORAGENICS INC (OGEN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OGEN research updated on 13F Pro?

OGEN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ORAGENICS INC(OGEN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1174940 OGEN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.4M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

OGEN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ORAGENICS INC (OGEN), a Healthcare sector company. OGEN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), ORAGENICS INC reports net income of $-2.2M, free cash flow of $-2.2M. Top institutional holders of OGEN by reported 13-F value include GEODE CAPITAL MANAGEMENT,, Pathstone Holdings,, TWO SIGMA SECURITIES,, based on the most recent SEC filings. OGEN trades on the NYSE exchange and files with the SEC under CIK 1174940. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OGEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ORAGENICS INC directly from SEC EDGAR.

Net Income

Q1 2026

$-2.2M

Free Cash Flow

Q1 2026

$-2.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2024

FY20 —FY22 $131.5KFY23 $37.7KFY24 —

Net Income

+94.9% YoY

$-1.1MFY 2024

FY20 $-26.4MFY22 $-14.3MFY23 $-20.7MFY24 $-1.1M

Operating Income

+49.5% YoY

$-10.6MFY 2024

FY20 $-26.6MFY22 $-14.4MFY23 $-20.9MFY24 $-10.6M

EPS (Diluted)

-421.6% YoY

$-47.88FY 2024

FY20 —FY22 $-7.11FY23 $-9.18FY24 $-47.88

Total Assets

-70.4% YoY

$1.5MFY 2024

FY20 $18.7MFY22 $14.8MFY23 $5.0MFY24 $1.5M

Op. Cash Flow

-17.9% YoY

$-8.6MFY 2024

FY20 $-17.0MFY22 $-15.2MFY23 $-7.3MFY24 $-8.6M

Metric	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019	FY 2017
Revenue	—	$37.7K -71.4%	$131.5K	—	—	$0.00
Net Income	$-1.1M +94.9%	$-20.7M -44.6%	$-14.3M +45.9%	$-26.4M -69.8%	$-15.6M -131.2%	$-6.7M
Operating Income	$-10.6M +49.5%	$-20.9M -45.0%	$-14.4M +45.9%	$-26.6M -67.8%	$-15.9M -136.3%	$-6.7M
EPS (Diluted)	$-47.88 -421.6%	$-9.18 -29.1%	$-7.11	—	—	—
Total Assets	$1.5M -70.4%	$5.0M -66.3%	$14.8M -21.0%	$18.7M -5.4%	$19.8M +173.8%	$7.2M
Operating Cash Flow	$-8.6M -17.9%	$-7.3M +52.1%	$-15.2M +10.2%	$-17.0M -30.3%	$-13.0M -104.5%	$-6.4M

AI Insight: OGEN Financial Trends

OGEN continues burning cash with zero revenue while equity volatility suggests ongoing equity financing challenges.

• Company generated zero revenue across all reported quarters while maintaining consistent $2-3M quarterly operating losses.

• Equity swung dramatically from $-2M in Q2 2025 to $10M in Q3 2025, then declined to $6M by Q1 2026.

• Operating cash flow deteriorated from $-1M in Q2 2025 to $-3M in Q4 2025 before improving to $-2M in Q1 2026.

⚠ Company operates with no debt financing, making it entirely dependent on equity markets for survival funding.

⚠ Equity volatility indicates potential dilutive equity raises followed by continued cash burn without revenue generation.

AI Insight: OGEN Ratio Trends

Data is too sparse to identify meaningful trends, with only sporadic ROE and ROA figures available across quarters.

• ROE improved from -124.8% in Q3 2025 to -110.5% in Q4 2025 before deteriorating to -142.4% in Q1 2026.

• ROA showed marginal improvement from -96.5% in Q3 2025 to -90.9% in Q4 2025.

⚠ Persistent triple-digit negative returns indicate severe operational challenges requiring close monitoring of turnaround progress.

Get alerted when OGEN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ORAGENICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OGEN

GEODE CAPITAL MANAGEMENT, LLC
$36.4K65,072 sh
Pathstone Holdings, LLC
$30.8K55,001 sh
TWO SIGMA SECURITIES, LLC
$11.4K20,343 sh
UBS Group AG
$2.9K5,205 sh
Tower Research Capital LLC (TRC)
$2.5K4,548 sh
Ameritas Advisory Services, LLC
$1.1K2,000 sh
Western Wealth Management, LLC
$561.001,001 sh
BlackRock, Inc.
$394.00703 sh
St. Johns Investment Management Company, LLC
$112.00200 sh
HARBOUR INVESTMENTS, INC.
$19.0034 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$36.4K	65,072
Pathstone Holdings, LLC	$30.8K	55,001
TWO SIGMA SECURITIES, LLC	$11.4K	20,343
UBS Group AG	$2.9K	5,205
Tower Research Capital LLC (TRC)	$2.5K	4,548
Ameritas Advisory Services, LLC	$1.1K	2,000
Western Wealth Management, LLC	$561.00	1,001
BlackRock, Inc.	$394.00	703
St. Johns Investment Management Company, LLC	$112.00	200
HARBOUR INVESTMENTS, INC.	$19.00	34

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OGEN on your watchlist

Track score changes the day ORAGENICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OGEN a good stock to buy?

13F Pro's AI-powered analysis of ORAGENICS INC (OGEN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OGEN are available on the OGEN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OGEN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OGEN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ORAGENICS INC's investment landscape.